Structural Definition of a Unique Neutralization Epitope on the Receptor-Binding Domain of MERS-CoV Spike Glycoprotein

Cell Reports

Volumn 24, Issue 2, 2018, Pages 441-452

  Zhang, Senyan ^a   Zhou, Panpan ^b   Wang, Pengfei ^a   Li, Yangyang ^b   Jiang, Liwei ^b   Jia, Wenxu ^b   Wang, Han ^b   Fan, Angela ^b   Wang, Dongli ^a   Shi, Xuanling ^b   Fang, Xianyang ^a   Hammel, Michal ^c   Wang, Shuying ^d   Wang, Xinquan ^a,e   Zhang, Linqi ^b  

^a TSINGHUA UNIVERSITY   (China)

^b Tsinghua University   (China)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e SICHUAN UNIVERSITY   (China)

Author keywords

antibody epitope; coronavirus; crystal structure; Middle East respiratory syndrome; neutralizing antibody

Indexed keywords

CORONAVIRUS SPIKE GLYCOPROTEIN; DIPEPTIDYL PEPTIDASE IV; EPITOPE; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY MERS 4; UNCLASSIFIED DRUG; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; SITE DIRECTED MUTAGENESIS; STRUCTURAL MODEL; STRUCTURE ANALYSIS; VIRUS NEUTRALIZATION; BINDING SITE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN MULTIMERIZATION;

ANTIBODIES, NEUTRALIZING; BINDING SITES; EPITOPES; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN DOMAINS; PROTEIN MULTIMERIZATION; SPIKE GLYCOPROTEIN, CORONAVIRUS;

EID: 85049315642     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.06.041     Document Type: Article

References (53)

1. Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.W., Ioerger, T.R., McCoy, A.J., Moriarty, N.W., Read, R.J., Sacchettini, J.C., Sauter, N.K., Terwilliger, T.C., PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58 (2002), 1948–1954.
2. Assiri, A., McGeer, A., Perl, T.M., Price, C.S., Al Rabeeah, A.A., Cummings, D.A., Alabdullatif, Z.N., Assad, M., Almulhim, A., Makhdoom, H., et al., KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N. Engl. J. Med. 369 (2013), 407–416.
3. Barnes, C.O., Gristick, H.B., Freund, N.T., Escolano, A., Lyubimov, A.Y., Hartweger, H., West, A.P. Jr., Cohen, A.E., Nussenzweig, M.C., Bjorkman, P.J., Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nat. Commun., 9, 2018, 1251.
4. Bermingham, A., Chand, M.A., Brown, C.S., Aarons, E., Tong, C., Langrish, C., Hoschler, K., Brown, K., Galiano, M., Myers, R., et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill., 17, 2012, 20290.
5. Chen, P.R., Groff, D., Guo, J., Ou, W., Cellitti, S., Geierstanger, B.H., Schultz, P.G., A facile system for encoding unnatural amino acids in mammalian cells. Angew. Chem. Int. Engl. 48 (2009), 4052–4055.
6. Chen, Y., Rajashankar, K.R., Yang, Y., Agnihothram, S.S., Liu, C., Lin, Y.-L., Baric, R.S., Li, F., Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J. Virol. 87 (2013), 10777–10783.
7. Chen, Y., Lu, S., Jia, H., Deng, Y., Zhou, J., Huang, B., Yu, Y., Lan, J., Wang, W., Lou, Y., et al. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg. Microbes Infect., 6, 2017, e37.
8. Chen, Z., Bao, L., Chen, C., Zou, T., Xue, Y., Li, F., Lv, Q., Gu, S., Gao, X., Cui, S., et al. Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset. J. Infect. Dis. 215 (2017), 1807–1815.
9. Choi, J.Y., An outbreak of Middle East respiratory syndrome coronavirus infection in South Korea, 2015. Yonsei Med. J. 56 (2015), 1174–1176.
10. Chou, T.C., Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70 (2010), 440–446.
11. Chou, T.C., Talalay, P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984), 27–55.
12. Classen, S., Hura, G.L., Holton, J.M., Rambo, R.P., Rodic, I., McGuire, P.J., Dyer, K., Hammel, M., Meigs, G., Frankel, K.A., Tainer, J.A., Implementation and performance of SIBYLS: a dual endstation small-angle X-ray scattering and macromolecular crystallography beamline at the Advanced Light Source. J. Appl. Cryst. 46 (2013), 1–13.
13. Corti, D., Zhao, J., Pedotti, M., Simonelli, L., Agnihothram, S., Fett, C., Fernandez-Rodriguez, B., Foglierini, M., Agatic, G., Vanzetta, F., et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl. Acad. Sci. USA 112 (2015), 10473–10478.
14. de Wit, E., van Doremalen, N., Falzarano, D., Munster, V.J., SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14 (2016), 523–534.
15. Du, L., Zhao, G., Yang, Y., Qiu, H., Wang, L., Kou, Z., Tao, X., Yu, H., Sun, S., Tseng, C.T., et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J. Virol. 88 (2014), 7045–7053.
16. Emsley, P., Cowtan, K., Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004), 2126–2132.
17. Graham, R.L., Donaldson, E.F., Baric, R.S., A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Rev. Microbiol. 11 (2013), 836–848.
18. Gui, M., Song, W., Zhou, H., Xu, J., Chen, S., Xiang, Y., Wang, X., Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 27 (2017), 119–129.
19. Guinier, A., Fournet, F., Small Angle Scattering of X-rays. 1955, Wiley Interscience.
20. Haagmans, B.L., Al Dhahiry, S.H., Reusken, C.B., Raj, V.S., Galiano, M., Myers, R., Godeke, G.J., Jonges, M., Farag, E., Diab, A., et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect. Dis. 14 (2014), 140–145.
21. Hemida, M.G., Chu, D.K., Poon, L.L., Perera, R.A., Alhammadi, M.A., Ng, H.Y., Siu, L.Y., Guan, Y., Alnaeem, A., Peiris, M., MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg. Infect. Dis. 20 (2014), 1231–1234.
22. Hura, G.L., Menon, A.L., Hammel, M., Rambo, R.P., Poole, F.L. 2nd, Tsutakawa, S.E., Jenney, F.E. Jr., Classen, S., Frankel, K.A., Hopkins, R.C., et al. Robust, high-throughput solution structural analyses by small angle X-ray scattering (SAXS). Nat. Methods 6 (2009), 606–612.
23. Jiang, L., Wang, N., Zuo, T., Shi, X., Poon, K.M., Wu, Y., Gao, F., Li, D., Wang, R., Guo, J., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci. Transl. Med., 6, 2014, 234ra59.
24. Keck, Z., Wang, W., Wang, Y., Lau, P., Carlsen, T.H., Prentoe, J., Xia, J., Patel, A.H., Bukh, J., Foung, S.K., Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J. Virol. 87 (2013), 37–51.
25. Laskowski, R.A., MacArthur, M.W., Moss, D.S., Thornton, J.M., PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993), 283–291.
26. Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., Wang, Q., Lu, X., Wu, Y., Liu, W., et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res. 25 (2015), 1237–1249.
27. Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., Zhang, Y., Zhang, W., Yuan, Y., Bao, J., et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500 (2013), 227–231.
28. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Cryst. 40 (2007), 658–674.
29. Mouquet, H., Scharf, L., Euler, Z., Liu, Y., Eden, C., Scheid, J.F., Halper-Stromberg, A., Gnanapragasam, P.N., Spencer, D.I., Seaman, M.S., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 109 (2012), E3268–E3277.
30. Otwinowski, Z., Minor, W., Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997), 307–326.
31. Pallesen, J., Wang, N., Corbett, K.S., Wrapp, D., Kirchdoerfer, R.N., Turner, H.L., Cottrell, C.A., Becker, M.M., Wang, L., Shi, W., et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA 114 (2017), E7348–E7357.
32. Pascal, K.E., Coleman, C.M., Mujica, A.O., Kamat, V., Badithe, A., Fairhurst, J., Hunt, C., Strein, J., Berrebi, A., Sisk, J.M., et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl. Acad. Sci. USA 112 (2015), 8738–8743.
33. Peiris, J.S., Guan, Y., Yuen, K.Y., Severe acute respiratory syndrome. Nat. Med. 10:Suppl 12 (2004), S88–S97.
34. Pejchal, R., Doores, K.J., Walker, L.M., Khayat, R., Huang, P.S., Wang, S.K., Stanfield, R.L., Julien, J.P., Ramos, A., Crispin, M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334 (2011), 1097–1103.
35. Pelikan, M., Hura, G.L., Hammel, M., Structure and flexibility within proteins as identified through small angle X-ray scattering. Gen. Physiol. Biophys. 28 (2009), 174–189.
36. Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Müller, M.A., Dijkman, R., Muth, D., Demmers, J.A., Zaki, A., Fouchier, R.A., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495 (2013), 251–254.
37. Ren, H., Zhou, P., Epitope-focused vaccine design against influenza A and B viruses. Curr. Opin. Immunol. 42 (2016), 83–90.
38. Sali, A., Blundell, T.L., Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234 (1993), 779–815.
39. Schneidman-Duhovny, D., Hammel, M., Tainer, J.A., Sali, A., Accurate SAXS profile computation and its assessment by contrast variation experiments. Biophys. J. 105 (2013), 962–974.
40. Schneidman-Duhovny, D., Hammel, M., Tainer, J.A., Sali, A., FoXS, FoXSDock and MultiFoXS: single-state and multi-state structural modeling of proteins and their complexes based on SAXS profiles. Nucleic Acids Res. 44:W1 (2016), W424–W429.
41. Shang, H., Han, X., Shi, X., Zuo, T., Goldin, M., Chen, D., Han, B., Sun, W., Wu, H., Wang, X., Zhang, L., Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J. Biol. Chem. 286 (2011), 14531–14541.
42. Tang, X.C., Agnihothram, S.S., Jiao, Y., Stanhope, J., Graham, R.L., Peterson, E.C., Avnir, Y., Tallarico, A.S., Sheehan, J., Zhu, Q., et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. USA 111 (2014), E2018–E2026.
43. Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., Guo, D., Fu, L., Cui, Y., Liu, X., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23 (2013), 986–993.
44. Wang, L., Shi, W., Joyce, M.G., Modjarrad, K., Zhang, Y., Leung, K., Lees, C.R., Zhou, T., Yassine, H.M., Kanekiyo, M., et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun., 6, 2015, 7712.
45. Wang, Q.S., Yu, F., Huang, S., Sun, B., Zhang, K.H., Liu, K., Wang, Z.J., Xu, C.Y., Wang, S.S., Yang, L.F., et al. The macromolecular crystallography beamline of SSRF. Nucl. Sci. Tech. 26 (2015), 12–17.
46. Wang, L., Shi, W., Chappell, J.D., Joyce, M.G., Zhang, Y., Kanekiyo, M., Becker, M.M., van Doremalen, N., Fischer, R., Wang, N., et al. Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape. J. Virol., 92, 2018 e02002-17.
47. Wu, X., Kong, X.P., Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Curr. Opin. Immunol. 42 (2016), 56–64.
48. Ying, T., Du, L., Ju, T.W., Prabakaran, P., Lau, C.C., Lu, L., Liu, Q., Wang, L., Feng, Y., Wang, Y., et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J. Virol. 88 (2014), 7796–7805.
49. Ying, T., Prabakaran, P., Du, L., Shi, W., Feng, Y., Wang, Y., Wang, L., Li, W., Jiang, S., Dimitrov, D.S., Zhou, T., Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat. Commun., 6, 2015, 8223.
50. Yu, X., Zhang, S., Jiang, L., Cui, Y., Li, D., Wang, D., Wang, N., Fu, L., Shi, X., Li, Z., et al. Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci. Rep., 5, 2015, 13133.
51. Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., Lu, G., Wu, Y., Yan, J., Shi, Y., et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun., 8, 2017, 15092.
52. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367 (2012), 1814–1820.
53. Zumla, A., Chan, J.F., Azhar, E.I., Hui, D.S., Yuen, K.Y., Coronaviruses—drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15 (2016), 327–347.